AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Benitec Biopharma's 15min chart triggers MACD Death Cross and Bearish Marubozu
ByAinvest
Wednesday, Sep 10, 2025 11:10 am ET4min read
Benitec Biopharma's 15-minute chart has recently exhibited a MACD Death Cross and a Bearish Marubozu pattern, which suggests a high likelihood of a continued decline in the stock price. The bearish momentum appears to be sustained, with sellers dominating the market. This trend is expected to persist in the near term.
Benitec Biopharma's 15-minute chart has recently exhibited a MACD Death Cross and a Bearish Marubozu pattern, suggesting a high likelihood of a continued decline in the stock price. The bearish momentum appears to be sustained, with sellers dominating the market. This trend is expected to persist in the near term.The MACD (Moving Average Convergence Divergence) Death Cross is a technical indicator that signals a change in the trend of a security. When the MACD line crosses below the signal line, it indicates a bearish signal. The Bearish Marubozu pattern, characterized by a large body with minimal wicks, further supports this bearish trend, signaling strong selling conviction [1].
According to the 15-minute chart, the Bollinger Bands are currently expanding downward, indicating an increase in market volatility. The bearish Marubozu candlestick pattern, which was observed on September 9, 2025, at 13:00, aligns with the broader market conditions, suggesting that sellers are in control and that the downtrend is likely to persist .
Investors should closely monitor Benitec Biopharma's financial performance and technical indicators to make informed decisions. While these technical signals provide insights into potential stock price movements, investors should consider these signals in conjunction with fundamental analysis and broader market conditions.
Positive Outlook:
- Alnylam Pharma (ALNY) received a "Buy" rating from Jefferies with a price target of $384.00 [1].
- Chime Financial (CHYM) was initiated with an "Overweight" rating by multiple firms, including Morgan Stanley and Barclays, with targets ranging from $39.00 to $40.00 [1].
- CryoPort (CYRX) was rated "Buy" by BTIG Research with a price target of $10.00 [1].
- Datadog (DDOG) had its price target raised from $150.00 to $175.00 by Bank of America, reiterating a "Buy" rating [1].
- Energy Transfer (ET) was initiated with a "Buy" rating by TD Cowen with a price target of $22.00 [1].
- Grab (GRAB) was rated "Buy" by Jefferies with a price target of $5.70, indicating a 20.94% upside [1].
- Home Depot (HD) was rated "Buy" by TD Cowen with a price target of $470.00 [1].
- Intuit (INTU) was rated "Buy" by Morgan Stanley with a price target of $900.00 [1].
- JPMorgan Chase & Co. (JPM) had a $298.00 target set by Evercore ISI with an "Outperform" rating [1].
- Kinder Morgan (KMI) was initiated with a "Buy" rating by TD Cowen [1].
- Lam Research (LRCX) had its "Buy" rating reiterated by Citigroup [1].
- MACOM Technology Solutions (MTSI) had its target raised from $136.00 to $154.00 by Truist Financial, maintaining a "Buy" rating [1].
- Monopar Therapeutics (MNPR) was initiated with an "Overweight" rating by Cantor Fitzgerald and a target of $74.00 [1].
- Norwegian Cruise Line (NCLH) received a "Buy" rating from Jefferies with a price target of $29.00 [1].
- Oracle (ORCL) received a "Buy" rating from UBS with a $250.00 target [1].
- Oportun Financial (OPRT) was rated "Buy" at B. Riley Financial with an $11.00 price target [1].
- Ovintiv (OVV) was rated "Buy" at Barclays Capital with a price target of $55.00 [1].
- Phibro Animal Health (PAHC) was upgraded at JPMorgan Chase from Neutral to Overweight, with the price target raised from $25.00 to $35.00 [1].
- Progressive (PGR) was downgraded by Morgan Stanley from Overweight to Equal Weight, with a price target of $290.00 [1].
- Pulse Biosciences (PLSE) was initiated by Oppenheimer with an "Outperform" rating and a $22.00 price target [1].
- PTC (PTC) had its Overweight rating reiterated by KeyCorp Bank [1].
- Rockwell Automation (ROK) was initiated by CICC Research with a "Buy" rating and a price target of $320.00 [1].
Neutral Outlook:
- Allegiant Travel (ALGT) was initiated with a Neutral rating by UBS Group, with a price target lowered from $60.00 to $59.00 [1].
- Alaska Air Group (ALK) was initiated with a Neutral rating and a $49.00 price target by UBS Group [1].
- AvalonBay (AVB) was rated "Hold" by Evercore ISI with a price target of $229.00 [1].
- Benitec Biopharma (BNTC) was initiated with a "Buy" rating by TD Cowen [1].
- Broadridge Financial Solutions (BR) received a "Hold" rating from D.A. Davidson with a $220.00 target [1].
- Camden Property (CPT) was rated "Hold" by Evercore ISI with a price target of $124.00, implying a 13.26% upside [1].
- Citigroup (C) had a price target of $77.00 set by Evercore ISI, while Oppenheimer reiterated an "Outperform" rating [1].
- Coinbase Global (COIN) received a "Hold" rating from Goldman Sachs with a $268.00 price target [1].
- Coterra Energy (CTRA) was assigned a "Buy" rating by Barclays Capital with a $37.00 target [1].
- Crexendo (CXDO) was rated "Buy" at Northland Securities with a price target of $8.00 [1].
- Datadog (DDOG) had its price target raised from $150.00 to $175.00 by Bank of America, reiterating a "Buy" rating [1].
- DoubleVerify (DV) had its "Buy" rating reiterated by Craig Hallum [1].
- Emerson Electric Company (EMR) was rated "Buy" by TD Cowen, with a price target of $150.00 [1].
- Enovix (ENVX) received a "Buy" rating from Northland Securities with a $25.00 target [1].
- Enterprise Products Partners (EPD) was initiated with a "Hold" rating and a $33.00 price target by TD Cowen [1].
- Equity Residential (EQR) was upgraded by Evercore ISI from In-Line to Outperform, with a new target of $75.00, up from $74.00 [1].
- EQT Corp. (EQT) was initiated with an Overweight rating and a $65.00 target by Barclays [1].
- Essex Property (ESS) was rated "Hold" by Evercore ISI with a price target of $296.00 [1].
- Essent Group (ESNT) was downgraded from Outperform to Market Perform by Keefe, Bruyette & Woods, with a price target of $67.00 [1].
- Expand Energy (EXE) received a "Buy" rating from Northland Securities with a $25.00 target [1].
- First Republic Bank (FRC) was downgraded by Jefferies from Overweight to Hold, with a price target of $24.00 [1].
- Fiserv (FISV) was upgraded by Raymond James from Market Perform to Outperform, with a new target of $180.00, up from $175.00 [1].
- Five Below (FIVE) was rated "Hold" by Wedbush with a price target of $140.00 [1].
- Flextronics International (FLEX) was initiated with a "Buy" rating by Northland Securities with a price target of $15.00 [1].
- Global Payments (GPAY) was rated "Buy" by TD Cowen with a price target of $120.00 [1].
- HCA Healthcare (HCA) was rated "Buy" by TD Cowen with a price target of $340.00 [1].
Investors should remain cautious and monitor the stock closely for any changes in the technical indicators.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet